{"entity":{"id":"nct05425940","kind":"trial","name":"Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer","aka":[],"tldr":"A phase 3 trial of Zanzalintinib, Atezolizumab, Regorafenib in colorectal cancer, run by Exelixis, active and no longer recruiting.","summary":"Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer is a phase 3 interventional study registered as NCT05425940 by Exelixis, with 901 participants enrolled, started 2022-09-07 and due to reach its primary completion in 2026-06-16. Interventions recorded: XL092, Atezolizumab, Regorafenib. Conditions listed: Colorectal Cancer. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05425940","url":"https://clinicaltrials.gov/study/NCT05425940"}],"tags":["ctgov-ingest"],"related":[],"cancers":["colorectal"],"sections":[],"technologies":[],"targets":[],"drugs":["zanzalintinib","atezolizumab","regorafenib"],"companies":["exelixis"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05425940","phase":"3","setting":"A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer","sponsor":"Exelixis","enrolled":901,"outcomes":[]},"route":"/trials/nct05425940/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"}],"drug":[{"id":"atezolizumab","kind":"drug","name":"Atezolizumab","route":"/drugs/atezolizumab/"},{"id":"regorafenib","kind":"drug","name":"Regorafenib","route":"/drugs/regorafenib/"},{"id":"zanzalintinib","kind":"drug","name":"Zanzalintinib","route":"/drugs/zanzalintinib/"}],"company":[{"id":"exelixis","kind":"company","name":"Exelixis","route":"/companies/exelixis/"}]}}